Kymera Therapeutics
Tracked across 3 events · 18 articles · First seen Apr 13, 2026 · Last active Aug 10, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Kymera Therapeutics received Fast Track designation from the United States — Food and Drug Administration for its drug KT-621, which is expected to accelerate its development and potential approval for treating asthma.
Apr 13, 2026 · 6 articles
Business
Impact: Kymera Therapeutics appointed Penny Carlson as Senior Vice President, Development Operations, which is expected to strengthen its global clinical development operations. The company also announced the retirement of Jeremy Chadwick, its Chief Operating Officer, who will remain as an advisor.
Jun 08, 2026 · 6 articles
Business
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company developing oral therapies for neurologic diseases, announced the appointment of Elena Ridloff, CFA, to its Board of Directors, effective August 6, 2026. Ridloff brings over two decades…
Impact: Kymera Therapeutics is mentioned as a company where Ridloff serves on the board.
Aug 10, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Kymera Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard